Skip to Main Content

Paper Details

Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action.
JCI Insight
11
2020
-, AI, AI- or fulvestrant-resistant breast cancer cells, AI-resistant cells, Anastrozole, Aromatase, CSMD1, CSMD1 SNP, CUB And Sushi multiple domains 1, CYP19, ER, ER+, anastrozole, aromatase, breast cancer, estradiol, estrogen, estrogen receptor, exemestane, fulvestrant, fulvestrant-resistant breast cancers, letrozole, patients, postmenopausal breast cancer, resistant cells

Datasets

Release 1.2